Navigation Links
Oral bisphosphonate did not improve prognosis for patients with breast cancer
Date:12/7/2011

SAN ANTONIO Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.

Volker Mbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Hchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

Mbus and his colleagues randomly assigned 3,023 patients with breast cancer to two different chemotherapy regimens and then further assigned them to 50 milligrams of oral ibandronate or observation. After a median follow-up of 38.7 months, "we found no significant difference between groups in the primary endpoint" of disease-free survival, Mbus said.

He described these results as "disappointing" compared with other studies. In the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, for example, Mbus said that the subgroup of postmenopausal patients showed an improvement in recurrence-free and overall survival.

"So far, clinical trials of adjuvant bisphosphonates in early breast cancer have shown variable results, independent from their application (oral compared with intravenous)," Mbus said.

More recently, two trials the Austrian Breast & Colorectal Study Group (ABCSG-12) and the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) have shown significant benefit in patients with hormone receptor-positive breast cancer who were postmenopausal and received an endocrine treatment only.

Mbus said that in the AZURE trial, 95 percent of patients received chemotherapy and only postmenopausal patients showed an improvement in the zoledronic acid group. "In our [GAIN] trial, all patients received dose-dense chemotherapy, and unfortunately, we could not show a benefit in any subgroup," he said. "We speculate that the high efficacy of dose-dense chemotherapy erases the potential effect of bisphosphonates, which is shown in patients with endocrine treatment only."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Some bisphosphonates users unfamiliar with drugs possible side effects on oral health
2. New task force report on bisphosphonate use and atypical femur fractures in osteoporosis patients
3. Immediate bisphosphonate use with endocrine therapy reduced recurrence and increased survival in postmenopausal early breast cancer
4. A New Website Series Improves Appearance and Health City by City
5. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
6. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
7. NationalCreditReport.com Reminds Consumers of Ways to Improve Credit Report and Score in 2010
8. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
9. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
10. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
11. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... , ... Advice Media, the industry leader in digital marketing for medical practices, has been recognized ... included in the Inc. 5000 for the second time in two years. Shawn Miele, Chief ... 5000 rankings for the second year in a row. It’s extremely difficult to make this ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... , ... August 16, 2017 , ... An August 3rd article on Reuters ... subject of a report in JAMA (the Journal of the American Medical Association). The study ... able to achieve BMIs under 30, when compared to patients with lower BMIs. At present, ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Any ... Inc. 5000. The company ranked #4429 on the newly released, 36th annual Inc. ... represents a unique look at the most successful companies within the American economy’s most ...
(Date:8/16/2017)... ... 16, 2017 , ... QualDerm Partners , a company ... announced Cumberland Skin Surgery and Dermatology has joined the company as ... both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer care ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/3/2017)... SAN DIEGO , Aug. 3, 2017  Opioid ... crippling diseases driving up healthcare costs and threatening outcomes, ... the lab supply and IVD industry that support them, ... health care market researcher said that drugs of abuse, ... vendors and sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation ... day delivery service for patients in the Washington ... traditional retail pharmacy by providing delivery of medications through the ... for future delivery or delivered within one hour to any ... are excited to bring this invaluable service to ...
Breaking Medicine Technology: